# Nanoscale

# Accepted Manuscript



This is an *Accepted Manuscript*, which has been through the Royal Society of Chemistry peer review process and has been accepted for publication.

Accepted Manuscripts are published online shortly after acceptance, before technical editing, formatting and proof reading. Using this free service, authors can make their results available to the community, in citable form, before we publish the edited article. We will replace this Accepted Manuscript with the edited and formatted Advance Article as soon as it is available.

You can find more information about *Accepted Manuscripts* in the **Information for Authors**.

Please note that technical editing may introduce minor changes to the text and/or graphics, which may alter content. The journal's standard <u>Terms & Conditions</u> and the <u>Ethical guidelines</u> still apply. In no event shall the Royal Society of Chemistry be held responsible for any errors or omissions in this *Accepted Manuscript* or any consequences arising from the use of any information it contains.



www.rsc.org/nanoscale

Cite this: DOI: 10.1039/c0xx00000x

www.rsc.org/xxxxx

# **ARTICLE TYPE**

# Cu<sub>2-x</sub>Se@mSiO<sub>2</sub>-PEG Core-Shell Nanoparticles: a Low-Toxic and Efficient Difunctional Nanoplatform for Chemo-Photothermal Therapy under Near Infrared Light Radiation with a Safe Power Density

Xijian Liu,<sup>‡ab</sup> Qian Wang,<sup>‡ac</sup> Chun Li, <sup>a</sup> Rujia Zou,<sup>ad</sup> Bo Li,<sup>a</sup> Guosheng Song,<sup>a</sup> Kaibing Xu,<sup>a</sup> Yun Zheng<sup>e</sup> ₅ and Junqing Hu<sup>\*a</sup>

Received (in XXX, XXX) Xth XXXXXXXX 20XX, Accepted Xth XXXXXXXX 20XX DOI: 10.1039/b000000x

A low-toxic difunctional nanoplatform integrating both photothermal therapy and chemotherapy for killing cancer cells using Cu<sub>2-x</sub>Se@mSiO<sub>2</sub>-PEG core-shell nanoparticles is reported. Silica coating and

- <sup>10</sup> further PEG modifying improve the hydrophilicity and biocompatibility of copper selenide nanoparticles. As-prepared Cu<sub>2-x</sub>Se@mSiO<sub>2</sub>-PEG nanoparticles not only display strong near infrared (NIR) region absorption and good photothermal effect, but also exhibit excellent biocompatibility. The mesoporous silica shell is provided as the carrier for loading anticancer drug, doxorubicin (DOX). Moreover, the release of DOX from Cu<sub>2-x</sub>Se@mSiO<sub>2</sub>-PEG core-shell nanoparticles can be triggered by pH and NIR
- <sup>15</sup> light, resulting in a synergistic effect for killing cancer cell. Importantly, the combination of photothermal therapy and chemotherapy driven by NIR radiation with safe power density significantly improves the therapeutic efficacy, and demonstrates better therapeutic effects for cancer treatment than individual therapy.

Keywords: Cu<sub>2-x</sub>Se@mSiO<sub>2</sub>, low-toxic, chemotherapy, controllable release, photothermal

## 20 1. Introduction

Photothermal therapy (PTT) that uses optical absorbing agents to "cook" cancer cells under light irradiation without damaging surrounding healthy tissue has attracted significant attention in recent years as a promising alternative or supplement to 25 traditional cancer therapies.<sup>1-3</sup> Ideal PTT agents should exhibit strong absorbance in the near-infrared (NIR) region ( $\lambda$ = 700-1300 nm), which is a therapeutic window due to high optical transparency of biological tissues,<sup>4</sup> and could efficiently transfer the absorbed NIR optical energy into heat. Furthermore, the PTT <sup>30</sup> agents should have good biocompatibility.<sup>1,2</sup> Currently, a series of NIR-light-absorbing nanomaterials have shown potential in PTT cancer treatment, such as gold nanorods,<sup>5,6</sup> gold shells,<sup>7,8</sup> gold cages,<sup>9-12</sup> palladium nanosheets,<sup>13,14</sup> carbon nanotubes,<sup>15,16</sup> graphene,<sup>17,18</sup> polypyrrole,<sup>1,2</sup> indocyanine dye,<sup>19</sup> W18O49 35 nanowires,<sup>20</sup> copper sulfide,<sup>21-24</sup> and copper selenide nanoparticles.<sup>25</sup> However, one of the major limitations of using PTT for clinical cancer treatment is the relatively high treatment power density of laser for the aim of obtaining sufficient heating in cancer cell killing, which probably hurts normal tissues.<sup>26</sup> For 40 clinical applications, the energy input of laser should be safe to avoid damage to healthy tissues and skins, which is always a primary concern for PTT. If PTT agents can integrate

nanoplatform for cancer destruction, the treatment power density <sup>45</sup> of laser will be effectively reduced, and skins and normal tissues can be avoided from harm. Numerous good results showed that the combination of photothermal therapy and chemotherapy had better effects on destroying cancer cells than chemotherapy or photothermal therapy alone due to the synergistic effect. For <sup>50</sup> instance, Au@SiO<sub>2</sub>,<sup>27,28</sup> Cu<sub>9</sub>S<sub>5</sub>@SiO<sub>2</sub>,<sup>29</sup> hollow mesoporous silica@Pd (HMSS-NH<sub>2</sub>@ Pd), <sup>30</sup> Pd@Ag@sSiO<sub>2</sub>@mSiO<sub>2</sub>-DihBen,<sup>31</sup> graphene@mSiO<sub>2</sub> (GSPI)<sup>32</sup> , DOX/ICG@lipidpolymer (DINPs)<sup>33</sup> and Fe<sub>3</sub>O<sub>4</sub>@PPy<sup>34</sup> nanocomposites have been fabricated and showed remarkable cancer-cell killing efficiency. <sup>55</sup> Therefore, the development of such novel multifunctional treatment systems combining photothermal therapy and chemotherapy with safe and efficient therapeutic effect is vital.

Recently, copper selenide has been supposed to be a promising candidate as a photothermal agent due to high <sup>60</sup> photothermal conversion efficiency and simple synthesis method.<sup>24,35</sup> However, copper selenide is hydrophobic and less biocompatible when synthesized via hot injection. Though the copper selenide was coated by polymer, a suspicious long-term toxicity in vitro<sup>25</sup> still limited its applications in vivo therapy. <sup>65</sup> Therefore, new methods of surface modification should be developed to further reduce the toxicity of copper selenide as PTT agents. Mesoporous silica nanoparticles (MSNs), which have shown excellent stability, non-cytotoxicity, tunable porosity

This journal is © The Royal Society of Chemistry [year]

photothermal therapy and other treatment modalities into a single

and facile modification,<sup>30,36</sup> appeal researchers to use them as a nanocarrier for multifunctional drug delivery in drug controllable release area. Thus mesoporous silica coating is a very efficient way to reduce toxicity of photothermal materials, and to be used s as anticancer drug carriers. So the combination of chemotherapy

and photothermal therapy in a platform will be achieved by mesoporous silica coating.

In this work, we designed and prepared Cu<sub>2-x</sub>Se@mSiO<sub>2</sub>-PEG

- core-shell nanoparticles by combining hot injection reaction and <sup>10</sup> sol-gel reaction, and then by surface modification with PEGylation. Because the  $Cu_{2-x}Se$  nanoparticles core can effectively convert NIR light into fatal heat due to the strong surface plasmon resonance (SPR) absorption, and the biocompatible mesoporous silica shell can provide the carrier for
- <sup>15</sup> loading anticancer drug, as-prepared Cu<sub>2-x</sub>Se@mSiO<sub>2</sub>-PEG coreshell nanoparticles can be used as a low-toxic difunctional nanoplatform integrating both photothermal therapy and chemotherapy for killing cancer cells under NIR radiation. In particular, the low pH in cellular endosomes and the heat
- <sup>20</sup> generated by the NIR irradiation can lead to rapid release of the DOX molecules loaded inside the mesoporous SiO<sub>2</sub> shells and enhance the chemotherapeutic effects of DOX. Cu<sub>2-x</sub>Se@mSiO<sub>2</sub>-PEG core-shell nanoparticles as a difunctional nanoplatform for chemo-photothermal therapy have at least three important for the second second
- <sup>25</sup> features: (1) Unlike chemo-photothermal therapy nanoplatforms based on noble-metal nanostructures that are limited by the high cost of noble-metal, Cu<sub>2-x</sub>Se@mSiO<sub>2</sub>-PEG nanoplatform is benefited from its low cost and simple synthetic route. (2) Cu<sub>2-x</sub>Se@mSiO<sub>2</sub>-PEG nanoplatform has an absorbance peak close to
- $_{30}$  980 nm, and guarantees high photothermal conversion ability when driven by the 980 nm laser. Also, the 980 nm light has deeper penetration depth in biological tissues than 808 nm light, and Cu<sub>2-x</sub>Se@mSiO<sub>2</sub>-PEG nanoplatform has good PTT effect when is driven at safe power density of 0.72 W/cm<sup>2</sup> (higher than
- <sup>35</sup> the 808 nm laser limit intensity set).<sup>23,24,37,38</sup> (3) The Cu<sub>2-x</sub>Se@mSiO<sub>2</sub> composites are modified by PEG, improving their colloidal stability and biocompatibility and decreasing immunogenicity in vivo therapy. <sup>28,29</sup> In our vitro and vivo experiments, the combination of photothermal therapy and a champetharapy significantly improves the therapytic officient.
- <sup>40</sup> chemotherapy significantly improves the therapeutic efficacy, and displays better therapeutic effects for cancer treatment than individual therapy.

# 2. Experimental Section

- **2.1. Chemicals and reagents.** All reagents were used without <sup>45</sup> further purification. Copper (I) chloride (CuCl), cetyltrimethylammonium bromide (CTAB), sodium hydroxide (NaOH) and anhydrous ethanol are analytically pure and were purchased from Sinopharm Chemical Reagent Co. (Shanghai, China), and tetraethylorthosilicate (TEOS, GR), selenium a powders, plain and playlaming (approximate C18 from 20)
- <sup>50</sup> powders, oleic acid, oleylamine (approximate C18 from 80-90%)were obtained from Aladdin, and 2-[Methoxy(polyethyleneoxy)propyl]-trimethoxysilane (PEG-silane, MW = 596-725 g/mol, 9-12 EO) was obtained from Gelest (Morrisville, PA) and doxorubicin hydrochloride (DOX) was got from Lunicod Taskingle as CO. Ltd. (DOX) was got

55 from Huafeng United Technology CO., Ltd. (Beijing, China)

**2.2. Characterization.** Sizes, morphologies, and microstructures of the nanoparticles were determined by a transmission electron

microscope (TEM; JEM-2100F). Powder X-ray diffraction (XRD) was conducted by a D/max-2550 PCX-ray diffractometer (Rigaku,

- <sup>60</sup> Japan). The surface area, pore size, and pore-size distribution of the products were determined by Brunauer-Emmett-Teller (BET) nitrogen adsorption-desorption and Barett-Joyner-Halenda (BJH) methods (Micromeritics, ASAP2020). Fourier transform infrared (FTIR) spectra were measured using an IRPRESTIGE-21
   <sup>65</sup> spectrometer (Shimadzu) using the KBr pressed pellets. UVvisible absorption spectra were measured on UV-Vis 1901 Spectrophotometer (Phoenix) using quartz cuvettes with an optical path of 1 cm. Content of copper ions and Au ions in the
- solution was determined by a Leeman Laboratories Prodigy high-<sup>70</sup> dispersion inductively coupled plasma atomic emission spectroscopy (ICP-AES).

2.3. Synthesis of Cu<sub>2-x</sub>Se nanocrystal. Cu<sub>2-x</sub>Se nanocrystals were prepared by a modified thermal injection method described previously.35 In a typical procedure, 39.5 mg of selenium 75 powders and 5 mL of oleic acid (OA) in a flask were heated at 120 °C with flowing nitrogen for 30 min in order to remove any moisture and oxygen and subsequently were heated to 280 °C under magnetic stirring for 30 min. Then Se-OA precursor was synthesized for followed use. In another flask, the mixtures of 5 80 mL of OA, 5mL of oleylamine (OAM) and 49.5 mg of CuCl were heated at 120 °C with flowing nitrogen for 30 min and subsequently were heated to 220 °C under magnetic stirring. Then 5 mL of Se-OA precursor was injected into the above copper precursors, forming dark solution immediately, and then 85 was maintained at 220 °C for 5 min. Subsequently the reaction solution rapidly cooled to 60 °C. Then ethanol was added to the reaction solution followed by centrifuging at 12000 rpm for 10min. This procedure was repeated twice to remove residual surfactants. Finally, the Cu<sub>2,x</sub>Se nanocrystals were dispersed in 10 90 mL of chloroform for later use.

2.4. Synthesis of CTAB-stabilized Cu<sub>2-x</sub>Se nanocrystals (Cu<sub>2-x</sub>Se-CTAB). A phase transfer of as-prepared Cu<sub>2-x</sub>Se nanocrystals from chloroform to water proceeded by a modified method described previously.<sup>29, 39</sup> First, the above 10 mL of chloroform
<sup>95</sup> solution containing the as-prepared Cu<sub>2-x</sub>Se nanocrystals was mixed with CTAB solution (1.5 g CTAB in 75 mL of water). By vigorous stiring at 40 °C for 36 h, a brown oil-in-water microemulsion formed, and then the chloroform was completely boiled off by rotary evaporation. Above solution was filtered through a 0.22 µm of millipore filter to remove impurities and then diluted to 75 mL with deionized water, forming in a transparent dark green solution of Cu<sub>2-x</sub>Se-CTAB. In order to prevent CTAB precipitation, the filtration of process and store of Cu<sub>2-x</sub>Se-CTAB solution should be kept above 25 °C.

<sup>105</sup> **2.5.** Synthesis of Cu<sub>2-x</sub>Se @mSiO<sub>2</sub>-PEG core-shell nanoparticles. The above 50 mL of the Cu<sub>2-x</sub>Se-CTAB solution was treated by ultrasonication and further continuously stirred for 1 h at 40 °C. Then, 3 mL of ethanol and 100  $\mu$ L of NaOH solution (30 mg/mL) were added to the above solution. After <sup>110</sup> stirred for several minutes, 100  $\mu$ L of TEOS was dropped into this mixture. The mixture was allowed to react for 1.5 h at 40 °C under continuously stirring. Subsequently, 100  $\mu$ L of PEG-silane was added under stirring for another 6.5 h and Cu<sub>2-x</sub>Se @mSiO<sub>2</sub>-PEG core-shell nanoparticles mixture was obtained. The synthesized product was centrifuged (12000 rpm, 10 min), washed with ethanol three times. Then the products were transferred to the ethanol solution of  $NH_4NO_3$  (50 mL, 10 mg/mL) and stirred at 50 °C for 2 h, the template of CTAB was removed

s through ion exchange. After that, as-prepared  $Cu_{2-x}Se$  @mSiO<sub>2</sub>-PEG nanoparticles were washed with ethanol three times. The final products were dispersed into deionized water and stored at 4 °C for further use.

**2.6. Measurement of photothermal performance.** <sup>10</sup> Measurement of photothermal performance was referenced our previous method.<sup>29</sup> The Cu<sub>2-x</sub>Se@mSiO<sub>2</sub>-PEG nanoparticles and Au nanorods aqueous dispersions (0.3 mL) of different concentrations (10, 25, 50, 100, 200, 400 mg/mL) were irradiated by laser (980 nm) for 8 min. The light source was an external

- <sup>15</sup> adjustable power (0-0.3 W) 980 nm semiconductor laser device with a 5 mm diameter laser module (Xi'an Tours Radium Hirsh Laser Technology Co., Ltd. China). The output power density was independently calibrated using a handy optical power meter (Newport model 1918-C, CA, USA) and was found to be ~ 0.72
- <sup>20</sup> W/cm<sup>2</sup>. The temperature of the solutions was measured by a digital thermometer (with an accuracy of 0.1 °C) with a thermocouple probe every 5 s.

**2.7. DOX loading and in vitro release.** 5 mg of  $Cu_{2-x}Se$ @mSiO<sub>2</sub>-PEG nanoparticles were dispersed in 10 mL of PBS <sup>25</sup> solution (pH 7.4) containing DOX (0.15 mg/mL). The mixture was stirred at room temperature for 48 h under dark conditions. The DOX-loaded  $Cu_{2-x}Se$  @mSiO<sub>2</sub>-PEG ( $Cu_{2-x}Se$ @mSiO<sub>2</sub>-PEG

/DOX) nanocomposites were collected by centrifugation at 12000 rpm for 12 min and were washed several times with water until

- <sup>30</sup> the supernatant became colorless. All supernatants were collected together. The amount of loaded DOX for Cu<sub>2-x</sub>Se@mSiO<sub>2</sub>-PEG was analyzed by a UV-Vis spectrophotometer at 482 nm and calculated as bellow. Encapsulation efficiency = (weight of DOX loaded into the Cu<sub>2-x</sub>Se@mSiO<sub>2</sub>-PEG)/(initial weight of DOX),
- $_{35}$  loading content = (weight of DOX loaded into the Cu<sub>2</sub>.  $_x$ Se@mSiO<sub>2</sub>-PEG)/(weight of the Cu<sub>2-x</sub>Se@mSiO<sub>2</sub>-PEG + DOX loaded into the Cu<sub>2-x</sub>Se@mSiO<sub>2</sub>-PEG). The release behaviors were performed at room temperature. Above-prepared Cu<sub>2</sub>.  $_x$ Se@mSiO<sub>2</sub>-PEG/DOX complexes were dispersed in 5 mL of
- <sup>40</sup> buffer solution with ultrasonication at pH values of 7.4 and pH 4.8 respectively, and stirred at room temperature. At selected time intervals, the nanomaterials solutions were centrifuged (12,000 rpm, 10 min) and supernatants were withdrawn for analysis of DOX and the same volume of fresh buffers was added back to the
- <sup>45</sup> residual nanomaterials. The amounts of the released DOX in the supernatant solutions were analyzed by a UV-Vis spectrometer at 482 nm. To study that the DOX could release increased from the nanoparticles under laser irradiation, release media solutions were irradiated with the NIR laser (980 nm, 0.72W/cm<sup>2</sup>) for 5 min at
- 50 predetermined time intervals, and then centrifuged and supernatants withdrawn for analysis of DOX.

**2.8. Cell culture**. Cell culture was referenced method reported by the literatures.<sup>22,23, 40</sup> Human cervical carcinoma cell lines (HeLa) were continuously grown in 50 mL culture flask, incubated by

55 DMEM medium supplemented with 10% heat-inactivated fetal bovine serum, 100 μg/mL streptomycin, 100 U/mL penicillin in a humidified incubator under 5% CO<sub>2</sub> at 37 °C. **2.9.** In vitro cytotoxicity of the Cu<sub>2-x</sub>Se@mSiO<sub>2</sub>-PEG nanoparticles. The in vitro cytotoxicity was measured using the <sup>60</sup> MTT assay in human cervical carcinoma cell line.<sup>22,28</sup> HeLa cells were plated into a 96-well plate (1×10<sup>4</sup> cells per well) in a complete medium at 37 °C and 5% CO<sub>2</sub> for 24 h before the experiments. The culture medium was replaced and cells were incubated with complete medium containing the Cu<sub>2</sub>. <sup>65</sup> xSe@mSiO<sub>2</sub>-PEG core-shell nanoparticles at a series of concentrations at 37 °C with 5% CO<sub>2</sub> for further 24 h. Then the culture medium was replaced with fresh medium and MTT solution (10 µL, 5 mg/mL) was added to each well of the culture plate, and the cells were incubated in the CO<sub>2</sub> incubator for <sup>70</sup> another 4 h. The cells then were lysed by the addition of 100 µL of DMSO. The spectrophotometric absorbance of formazan was

measured using a plate reader at 570 nm. Four replicates were

done for each treatment group.

2.10. In vitro chemo-photothermal therapy. HeLa cells were 75 plated into a 96-well plate  $(1 \times 10^4 \text{ cells per well})$  in a complete medium at 37 °C and 5% CO<sub>2</sub> for 24 h before the experiments. The culture medium was replaced with complete medium containing the DOX, Cu<sub>2-x</sub>Se@mSiO<sub>2</sub>-PEG/DOX and Cu<sub>2-</sub> <sub>x</sub>Se@mSiO<sub>2</sub>-PEG at an equivalent DOX concentration. Cu<sub>2</sub>-<sup>80</sup> "Se@mSiO<sub>2</sub>-PEG and Cu<sub>2-x</sub>Se@mSiO<sub>2</sub>-PEG/DOX have equivalent Cu<sup>+</sup> concentration. After 4 h of incubation, the cells were washed by PBS to removed unbound material and replaced with fresh medium. The cells were treated with or without 980 nm laser (0.72 W/cm<sup>2</sup>) irradiation for 5 min, respectively, and 85 then incubated at 37 °C with 5% CO<sub>2</sub> for further 20 h. MTT assay was also carried out to quantify the cell viabilities. Four replicates were done for each treatment group.

2.11. In vivo chemo-photothermal therapy. The chemophotothermal therapy test of cancer cells in vivo were 90 respectively carried out by a modified method similar to reference.<sup>20,29</sup> The osteosarcoma bearing mice were from Shanghai tenth people's hospital. When the tumors inside the mice had grown to 5-10 mm in diameter, the mice were randomly allocated into three groups. The mice were first anaesthetized by 95 trichloroacetaldehyde hydrate (10 %) at a dosage of 40 mg/kg body weight. Then the mouse in group A was intratumorally injected with 0.10 mL of phosphate-buffered saline (PBS) solution containing Cu2-xSe@mSiO2-PEG nanoparticles (400  $\mu g/mL$ ), the mouse in group B was intratumorally injected with 100 0.10 mL PBS solution containing Cu<sub>2-x</sub>Se@mSiO<sub>2</sub>-PEG/DOX nanocomposites (400 µg/mL), while group C was intratumorally injected with 0.1 mL saline solution. After 1 h, the injected areas of mice from three groups were perpendicularly irradiated by the 980 nm wavelength laser devices at 0.72 W /cm<sup>2</sup> for 5 min. The 105 temperature of the tumors surface was measured by a photothermal therapy-monitoring system GX-A300 (Shanghai Guixin Corporation). The mice were killed 8 h after photothermal therapy, and tumors were removed, embedded in paraffin, and cryo-sectioned into 4 µ m slices. The slides were stained with 110 hematoxylin/eosin (H&E). The slices were examined under a Zeiss Axiovert 40 CFL inverted fluorescence microscope, and images were captured with a Zeiss AxioCam MRc5 digital camera.

2.12 In vivo antitumor effect. The osteosarcoma bearing mice

were from Shanghai Tenth People's Hospital. When the tumor volume inside the mice reached ~ 85 mm<sup>3</sup>. The mice were randomly allocated into four groups and intratumorally injected with 150  $\mu$ L of PBS, DOX, Cu<sub>2-x</sub>Se@mSiO<sub>2</sub>-PEG, and Cu<sub>2-s</sub> se@mSiO<sub>2</sub>-PEG/DOX solutions (DOX 5 0  $\mu$ g/mL, Cu<sub>2-x</sub>Se@mSiO<sub>2</sub>-PEG/DOX solutions (DOX 5 D)

- $_{s}$  se@mSiO<sub>2</sub>-PEG/DOX solutions (DOX 5 0 µg/mL, Cu<sub>2</sub>, se@mSiO<sub>2</sub>-PEG 320 µg/mL). After injection, tumors were irradiated with the NIR light (980 nm, 0.72 W/cm<sup>2</sup>) for 10 min. Tumor sizes were monitored per two days for 10 days. The length and width of the tumors were measured by a digital vernier caliper. The tumor volume was calculated according to the
- following formula: width<sup>2</sup> x length/2.

#### 3. RESULTS AND DICUSSION

Fig 1 illustrates the synthetic process of the Cu<sub>2-x</sub>Se@mSiO<sub>2</sub>-PEG core-shell nanoparticles and the theranostic principle based <sup>15</sup> on the unique properties of Cu<sub>2-x</sub>Se@mSiO<sub>2</sub>-PEG for cancer treatment. First, the Cu<sub>2-x</sub>Se nanocrystals as photothermal agents were synthesized, and coated by mesoporous silica forming Cu<sub>2-x</sub>Se@mSiO<sub>2</sub> core-shell nanoparticles. In order to enhance the biocompatibility and stability of Cu<sub>2-x</sub>Se@mSiO<sub>2</sub> in aqueous <sup>20</sup> solution, Cu<sub>2-x</sub>Se@mSiO<sub>2</sub> nanoparticles were further modified by

- PEG-silane on their outmost surfaces, forming Cu<sub>2-x</sub>Se@mSiO<sub>2</sub>-PEG core-shell nanoparticles. The anticancer drug DOX was loaded on mesoporous silica shell within the Cu<sub>2-x</sub>Se@mSiO<sub>2</sub>-PEG core-shell nanoparticles, forming Cu<sub>2-x</sub>Se@mSiO<sub>2</sub>-
- <sup>25</sup> PEG/DOX nanocomposites. The Cu<sub>2-x</sub>Se@mSiO<sub>2</sub>-PEG/DOX nanocomposites were internalized by cancer cells due to their good features. The Cu<sub>2-x</sub>Se cores inside nanocomposites operate as NIR light absorbing agents, which can effectively convert NIR light into heat resulting in rapid release of DOX, thus dual <sup>30</sup> therapeutic modes (photothermal therapy and chemotherapy) can
- achieve by the NIR radiation and result in a synergistic effect for killing cancer cell.



**Fig. 1** Schematic illustration of Cu<sub>2-x</sub>Se@mSiO<sub>2</sub>-PEG core-shell <sup>35</sup> nanoparticles preparation and application as a difunctional treatment platform for cancer treatment.

The hydrophobic  $Cu_{2-x}Se$  nanoparticles were first synthesized according to a reported protocol<sup>35</sup> with some modifications. The transmission electron microscope (TEM) images of the obtained <sup>40</sup>  $Cu_{2-x}Se$  nanocrystals showed an average diameter of ~12 nm and high crystallinity (Fig 2a, Fig S1a). Then, hydrophobic  $Cu_{2-x}Se$ nanoparticles were transferred into an aqueous phase by utilizing cetyltrimethylammonium bromide (CTAB) to endow hydrophilic property and facilitate the SiO<sub>2</sub> coating. In the silica-coating <sup>45</sup> process, CTAB formed a bilayer around the Cu<sub>2-x</sub>Se nanocrystals and acted as an organic template for preparing Cu<sub>2-x</sub>Se@mSiO<sub>2</sub> core-shell nanoparticles. The Cu<sub>2-x</sub>Se@mSiO<sub>2</sub>-PEG core-shell nanoparticles(x is 0.42 measured by ICP) were obtained by modifying Cu<sub>2-x</sub>Se@mSiO<sub>2</sub> nanoparticles with PEG-silane. Based <sup>50</sup> on TEM images of the fabricated Cu<sub>2-x</sub>Se@mSiO<sub>2</sub>-PEG coreshell nanoparticles (Figs 2b,c, Figs S1b,c), the Cu<sub>2-x</sub>Se nanocrystals are completely encapsulated into mesoporous SiO<sub>2</sub> shell with an estimated thickness of ~10 nm, and Cu<sub>2</sub>.



<sup>55</sup> Fig. 2 TEM images of (a) Cu<sub>2-x</sub>Se and (b,c) Cu<sub>2-x</sub>Se@mSiO<sub>2</sub>-PEG. (d) XRD patterns of the standard Cu<sub>2-x</sub>Se (lower), assynthesized Cu<sub>2-x</sub>Se (middle) and Cu<sub>2-x</sub>Se@mSiO<sub>2</sub>-PEG (upper). (e) Absorption spectra of Cu<sub>2-x</sub>Se-CTAB and Cu<sub>2-x</sub>Se@mSiO<sub>2</sub>-PEG, inset shows a photograph of Cu<sub>2-x</sub>Se@mSiO<sub>2</sub>-PEG
<sup>60</sup> dispersion solution. (f) N<sub>2</sub> adsorption-desorption isotherms (inset: the pore diameter distribution) of Cu<sub>2-x</sub>Se@mSiO<sub>2</sub>-PEG coreshell nanoparticles.

The phase structures of the as-obtained Cu2-xSe nanocrystals and Cu2-xSe@mSiO2-PEG nanoparticles were examined by XRD 65 pattern, as shown in Fig 2d. Several well-defined characteristic peaks such as (1, 1, 1), (2, 2, 0) and (3, 1, 1) exhibit the cubic phase, referenced by standard Cu<sub>2-x</sub>Se phase (JCPDS card no: 06-0680), while Cu<sub>2-x</sub>Se@mSiO<sub>2</sub>-PEG nanoparticles have a wide and weak peak at about 23° which is clearly due to amorphous 70 silica coating. The Cu<sub>2-x</sub>Se and Cu<sub>2-x</sub>Se@mSiO<sub>2</sub>-PEG nanoparticles were further investigated by high-resolution TEM (HRTEM). As shown in Fig S1a,d, interplane-distance of (111) crystal planes is 0.330 nm, corresponding to standard cubic Cu<sub>2</sub>. <sub>x</sub>Se phase and other researches.<sup>41</sup> It was proved that the Cu<sub>2-x</sub>Se 75 had cubic phase both before and after the silica coating. Since cubic phase is more stable for  $Cu_{2-x}Se$ ,<sup>42</sup> it is advantageous to use Cu<sub>2-x</sub>Se to acquire stable photothermal effect in photothermal therapy process. Absorption spectra of as-obtained Cu<sub>2-x</sub>SeCTAB and Cu<sub>2-x</sub>Se@mSiO<sub>2</sub>-PEG are shown in Fig 2e. Both Cu<sub>2-x</sub>Se-CTAB and Cu<sub>2-x</sub>Se@mSiO<sub>2</sub>-PEG nanoparticles show strong NIR region absorption. The as-prepared Cu<sub>2-x</sub>Se-CTAB nanoparticles have an absorbance peak at 1012 nm. After silicas shell coating, it exhibits a small red-shift (~ 24 nm). This

- phenomenon could be explained by the fact that the refractive index of the silica shell is larger than water.<sup>28</sup> The absorbance peak of  $Cu_{2-x}Se@mSiO_2-PEG$  is close to the wavelength (980 nm) of excitation laser, which is advantageous for full usage of the
- <sup>10</sup> SPR effect of materials, and enhancing photothermal efficiency.<sup>43</sup> Fig 2f showed the N<sub>2</sub> adsorption-desorption isotherm and pore size distribution (inset) of Cu<sub>2-x</sub>Se@mSiO<sub>2</sub>-PEG. The isotherm of Cu<sub>2-x</sub>Se@mSiO<sub>2</sub>-PEG after CTAB extraction displays a typical type IV feature. The BET (Brunauer-Emmett-Teller) surface area

<sup>15</sup> and total pore volume of the core-shell nanoparticles were measured to be 579 m<sup>2</sup>/g and 1.15 m<sup>3</sup>/g respectively. The pore size distribution (Fig 2f, inset) exhibits a sharp peak centered at a mean value of 2.8 nm. Thus, Cu<sub>2-x</sub>Se@mSiO<sub>2</sub>-PEG core-shell nanoparticles have large surface area and appropriate pore size, <sup>20</sup> which are favorable for drug loading.

PEG modification of the silica shells can improve colloidal stability, decrease immunogenicity and enhance the tumor targeting efficiency for in vivo applications, <sup>28, 44</sup> thus the Cu<sub>2-x</sub>Se@mSiO<sub>2</sub> core-shell nanoparticles were further grafted with <sup>25</sup> PEG-silane on their outmost surfaces via covalent bonding,

- <sup>25</sup> PEG-shahe on their outmost surfaces via covalent bonding, forming the Cu<sub>2-x</sub>Se@mSiO<sub>2</sub>-PEG core-shell nanoparticles. The Fourier transform infrared (FTIR) spectra of the Cu<sub>2-x</sub>Se@mSiO<sub>2</sub>-PEG core-shell nanoparticles and PEG-silane reactant are shown in Fig S2. The adsorption bands at 2980-2845 cm<sup>-1</sup> and <sup>30</sup> adsorption peaks at 1390 cm<sup>-1</sup> are assigned to the stretching vibrations and deformation vibration of methylene (CH<sub>2</sub>) respectively, in the long alkyl chain of the backbone of PEG.<sup>45</sup> Compared to PEG-silane reactant, the Cu<sub>2-x</sub>Se@mSiO<sub>2</sub>-PEG
- nanoparticles have similar adsorption bands at same area, <sup>35</sup> suggesting that the PEG is successfully grafted on the mesoporous silica surface. Besides, the Cu<sub>2-x</sub>Se@mSiO<sub>2</sub>-PEG core-shell nanoparticles show excellent colloidal stability. After a period of 7 days, there is no aggregation and negligible absorption reduction in the NIR region during the storage of Cu<sub>2-</sub> <sup>40</sup> <sub>x</sub>Se@mSiO<sub>2</sub>-PEG core-shell nanoparticles in water (Fig S3).

As-prepared  $Cu_{2-x}Se@mSiO_2-PEG$  nanoparticles in water (Fig 35). NIR absorption feature, making them a potential photothermal therapy agent. To investigate the photothermal effect generated by NIR laser irradiation, the temperatures of the solutions

<sup>45</sup> containing various concentrations of Cu<sub>2-x</sub>Se@mSiO<sub>2</sub>-PEG were measured under irradiation of 980 nm laser with a safe power density (0.72 W/cm<sup>2</sup>). As shown in Fig 3a, the temperature of Cu<sub>2-x</sub>Se@mSiO<sub>2</sub>-PEG aqueous solution at concentration of 200  $\mu$ g/mL(48.9 ppm Cu<sup>+</sup>)was raised from 25.0 °C to 45.3 °C after

- <sup>50</sup> 480 s NIR irradiation. In comparison, the temperature of the control experiment of pure water (0 μg/mL) and Au nanorods (50 ppm Au)was only increased respectively by 4.3 °C and 14.2 °C after irradiated by the NIR laser under the same conditions(Fig S4), which indicating Cu<sub>2-x</sub>Se@mSiO<sub>2</sub>-PEG nanoparticles have
- <sup>55</sup> better phototherml effect than widely used Au nanorods when they are driven by 980 nm laser at same metal ion concentration. Moreover, the higher concentration of Cu<sub>2-x</sub>Se@mSiO<sub>2</sub>-PEG nanoparticles, the higher the temperature elevation increased (Fig





**Fig.3** (a) Temperature change of the aqueous solution containing the  $Cu_{2-x}Se@mSiO_2$ -PEG nanoparticles with different concentrations under irradiation of the 980 nm laser at a safe <sup>65</sup> power density (0.72 W/cm<sup>2</sup>). (b) Plot of temperature elevation over a period of 480 s versus the aqueous dispersion of the  $Cu_{2-x}Se@mSiO_2$ -PEG nanoparticles.

Based on the mesoporous shell structures, the Cu<sub>2</sub>-<sub>x</sub>Se@mSiO<sub>2</sub>-PEG particles are expected to be suitable for 70 anticancer drug delivery. DOX was loaded into the Cu<sub>2-</sub> <sub>x</sub>Se@mSiO<sub>2</sub>-PEG nanoparticles by simply mixing DOX aqueous solutions for 48 h, and then repeated washing twice to remove unbound DOX, forming Cu<sub>2-x</sub>Se@mSiO<sub>2</sub>-PEG/DOX nanocomposites, and the aqueous solution of which shows a 75 bronzing color (Fig 4a, inset). After loaded with DOX, Cu2xSe@mSiO<sub>2</sub>-PEG/DOX complex still exhibits strong NIR absorbance of Cu2-xSe@mSiO2-PEG, and shows typical absorption peak of DOX near 480 nm region, which indicates the DOX has been successfully incorporated into the Cu<sub>2</sub>. <sup>80</sup> <sub>x</sub>Se@mSiO<sub>2</sub>-PEG core-shell nanoparticles (Fig 4a). The encapsulation efficiency and loading capacity of DOX on the Cu<sub>2-x</sub>Se@mSiO<sub>2</sub>-PEG particles reached up to 61.27% and 15.53% (by weight) as determined by UV-vis, respectively. The loading content is higher than the present core-shell <sup>85</sup> nanocomposites (Au@mSiO<sub>2</sub> core-shell nanostructures 14.5%,<sup>27</sup>  $Cu_9S_5(a)mSiO_2$ -PEG core-shell nanocomposites 13.76%<sup>29</sup>). The high encapsulation efficiency and loading capacity of DOX can 30 different



be assigned to large surface area and appropriate pore size of Cu<sub>2-</sub> <sub>x</sub>Se@mSiO<sub>2</sub>-PEG.

Fig. 4 (a) Absorption spectra of the DOX,  $Cu_{2-x}Se@mSiO_2$ -PEG and  $Cu_{2-x}Se@mSiO_2$ -PEG/DOX solutions. (b) The cumulative <sup>5</sup> release kinetics from the  $Cu_{2-x}Se@mSiO_2$ -PEG/DOX nanocomposites in phosphate-buffer saline (pH 7.4), phosphatebuffer saline (pH 6.5) and acetate buffer (pH 4.8) at room temperature with or without NIR laser irradiation by a safe power density (0.72 W/cm<sup>2</sup>).

- <sup>10</sup> The DOX release from the Cu<sub>2-x</sub>Se@mSiO<sub>2</sub>-PEG nanocomposites against buffer solution at pH 7.4, 6.5 and 4.8 was researched to simulate normal physiological environment, tumor cells environment and acidic cellular endosomes, respectively. As shown in Fig 4b, the release of DOX from the Cu<sub>2-x</sub>Se@mSiO<sub>2</sub>-
- <sup>15</sup> PEG nanoparticles strongly depended on the pH of the medium and the releasing time. Because DOX became more water soluble at low pH value due to the protonated daunosamine group,<sup>46</sup> much more rapid DOX release from Cu<sub>2-x</sub>Se@mSiO<sub>2</sub>-PEG nanoparticles at low pH value. At pH 7.4, DOX molecules are
- <sup>20</sup> barely released, indicating that Cu<sub>2-x</sub>Se@mSiO<sub>2</sub>-PEG nanoplatform releases very little DOX molecules in normal physiological environment and normal cells can be effectively avoided from hurt by DOX, but in tumor cells environment, DOX releases more rapidly and reaches 11.33% in 10h. At pH 4.8,
- <sup>25</sup> DOX releases as high as 31.67%, which always occurs when the nanocomposites are endocytosed by tumor cells. Thus, such a pH-sensitive release of DOX from Cu<sub>2-x</sub>Se@mSiO<sub>2</sub>-PEG is beneficial for cancer therapy.

Fig. 5 (a) Viabilities of HeLa cells incubated for 24 h with



of

concentrations

the

Cu<sub>2-x</sub>Se@mSiO<sub>2</sub>-PEG

nanoparticles. (b) Viabilities of HeLa cells after incubation with different concentrations of free DOX, Cu<sub>2-x</sub>Se@mSiO<sub>2</sub>-PEG and Cu<sub>2-x</sub>Se@mSiO<sub>2</sub>-PEG/DOX with or without 5 min of NIR irradiation (0.72 W/cm<sup>2</sup>, 980 nm). Cu<sub>2-x</sub>Se@mSiO<sub>2</sub>-PEG and Cu<sub>2-x</sub>Se@mSiO<sub>2</sub>-PEG/DOX have equivalent Cu<sup>+</sup> concentration at corresponding equal DOX point .

To investigate whether the NIR photothermal effect offered by Cu<sub>2-x</sub>Se nanoparticles could trigger the DOX release, the release kinetics of DOX from the Cu<sub>2-x</sub>Se@mSiO<sub>2</sub>-PEG/DOX under NIR 40 laser irradiation was studied. During the DOX release process from the Cu2-xSe@mSiO2-PEG nanoparticles in the buffer solution at pH = 4.8, 6.5 and 7.4, 5 min NIR laser irradiations (980nm, 0.72 W/cm<sup>2</sup>) were given at 1.0, 2.0, 3.0, 4.0, 6.0, 8.0 and 10.0 h. As shown in Fig 4b, the first 5 min of NIR irradiation at 45 1.0 h increased the cumulative release of DOX from 11.6% to 19.5% at pH 4.8 and from 2.1% to 3.9% at pH 6.5. At other cycles, the same phenomena that a rapid release upon NIR irradiation and slow release rate without NIR irradiation was observed. At pH 4.8, the DOX cumulative release reached to 50 56.5% within 10 h after seven cycles of 5 min irradiation at given time intervals, while only 31.7% DOX was released without irradiation. At pH 6.5, an increase of 10 h DOX release from 10.3 to 20.1% was also achieved by NIR irradiation. The enhanced drug release under NIR irradiation can be attributed to heat 55 generated by photothermal effect of Cu<sub>2-x</sub>Se@mSiO<sub>2</sub>-PEG nanoparticles. The heat dissociates the strong interactions between DOX and SiO2, 28 thus more DOX molecules are released. These results demonstrate that the  $Cu_{2\text{-}x}Se@mSiO_2\text{-}$  PEG have successfully achieved the drug controllable release by pH and NIR light.

- As discussed above,  $Cu_{2-x}Se@mSiO_2$ -PEG nanoparticles have s excellent photothermal and drug delivery effects. But the ideal photothermal agent also should be nontoxic or low toxic for biological applications. So we first incubated HeLa cells with the  $Cu_{2-x}Se@mSiO_2$ -PEG particles at different concentrations for 24 h and then tested the cell viabilities by using the 3-(4,5-
- <sup>10</sup> dimethylthiazol-2-yl)-2,5-diphenyltetr azolium bromide (MTT) assay. No significant differences in the cell proliferation were observed in the absence or presence of  $Cu_{2-x}Se@mSiO_2-PEG$ nanoparticles (Fig. 5a). Even at the highest tested dose of  $Cu_{2-x}Se@mSiO_2-PEG$  nanoparticles (500 µg/mL), cell viability still
- <sup>15</sup> remained approximately 96.3%. These data show that the aqueous dispersion of  $Cu_{2-x}Se@mSiO_2$ -PEG nanoparticles (<500 µg/mL) can be considered to have low cytotoxicity.



**Fig. 6** (a) Plots of the temperature within the irradiated tumor area in three mice injected respectively with saline solution,  $Cu_{2-}$  $_{x}Se@mSiO_{2}$ -PEG and  $Cu_{2-x}Se@mSiO_{2}$ -PEG/DOX solution as a function of irradiation time, respectively, H&E-stained histological images of (b) injected saline solution, (c) injected  $Cu_{2-x}Se@mSiO_{2}$ -PEG solution, and (d) injected  $Cu_{2-x}Se@mSiO_{2}$ -PEG/DOX solution groups of mice after 5 minutes laser  $_{25}$  irradiation, respectively.

To investigate the effect of photothermal therapy, chemotherapy and their combination in vitro, HeLa cell incubated with different concentrations of free DOX,  $Cu_{2-x}Se@mSiO_2$ -PEG/DOX,  $Cu_{2-x}Se@mSiO_2$ -PEG/DOX treated with or without NIR irradiation at safe power density (0.72 W/cm<sup>2</sup>), and then the MTT assay was carried out to test the cell viability. The  $Cu_{2-x}Se@mSiO_2$ -PEG/DOX nanoparticles demonstrated higher cytotoxicity than free DOX at the same concentrations (Fig. 5b). The  $Cu_{2-x}Se@mSiO_2$ -PEG/DOX at the same concentrations (Fig. 5b).

- $_{35}$  PEG/DOX nanocomposites at an equivalent DOX concentration of 40 µg/mL killed about 46% of cells, but free DOX killed only 37.3% cells at same condition. This result can be explained by that DOX-loaded nanoparticles can enter cancer cells more easily than free DOX.<sup>30,31</sup> After uptake by cancer cells, the Cu<sub>2</sub>.
- <sup>40</sup> <sub>x</sub>Se@mSiO<sub>2</sub>-PEG/DOX nanocomposites experience a low-pH that induces rapid release of the loaded DOX inside the cells. After NIR laser irradiation (0.72 W/cm<sup>2</sup>, 980 nm), the Cu<sub>2-x</sub>Se@mSiO<sub>2</sub>-PEG/DOX particles exhibited a higher cell-killing effect in HeLa cells at all tested concentrations than the

<sup>45</sup> chemotherapy (without NIR irradiation) or the photothermal therapy (without DOX) alone. For example, 63.5% of the cells were killed by the  $Cu_{2-x}Se@mSiO_2-PEG/DOX$  nanoparticles with NIR irradiation at an equivalent DOX concentration of  $20\mu g/mL$ . However, 43.9% of the cells were killed by the  $Cu_{2-x}Se@mSiO_2$ -

<sup>50</sup> PEG/DOX nanoparticles without NIR irradiation. In the absence of DOX, the Cu<sub>2-x</sub>Se@mSiO<sub>2</sub>-PEG(Cu<sup>+</sup> concentration is identical as Cu<sub>2-x</sub>Se@mSiO<sub>2</sub>-PEG/DOX ) under NIR irradiation killed only 34.4% of the cells. Therefore, these results suggest that asprepared Cu<sub>2-x</sub>Se@mSiO<sub>2</sub>-PEG nanoparticles can act as a difunctional nanoplatform for chemo-photothermal therapy to effectively kill cancer driven by NIR irradiation at safe power density, and more importantly, the combination of photothermal therapy and chemotherapy demonstrates better therapeutic effects for cancer treatment than individual therapy.

<sup>60</sup> The Cu<sub>2-x</sub>Se@mSiO<sub>2</sub>-PEG core-shell nanoparticles have good photothermal conversion effect, high drug loading capacity, pH-dependent and NIR light-triggered drug release abilities, dual therapeutic modes (DOX release for chemotherapy and hyperthermia) in vitro characteristics. Because of the complexity <sup>65</sup> of in vivo environment, the efficacy should be examined in vivo therapy before clinical trials in humans. The osteosarcoma bearing mice were from Shanghai tenth people's hospital. When the tumors inside the mice had grown to 5-10 mm in diameter, the mice were randomly allocated into three groups. The mouse <sup>70</sup> in group A was intratumorally injected with 0.10 mL of the Cu<sub>2-x</sub>Se@mSiO<sub>2</sub>-PEG/DOX (400 µg/mL) nanocomposites'

dispersion solution, while group C was intratumorally injected 75 with 0.1mL saline solution. After 1 h, the injected areas of the mice from three groups were perpendicularly irradiated by the 980 nm wavelength laser devices (0.72 W /cm<sup>2</sup>) for 5 min. For the mouse treated with saline solution, the surface temperature of the tumor increased only 3.5 °C during the entire irradiation 80 process (Fig. 6a). In contrast, as to the Cu<sub>2.x</sub>Se@mSiO<sub>2</sub>-PEG

- <sup>80</sup> process (Fig. 6a). In contrast, as to the  $Cu_{2-x}Se@mSiO_2-PEG$ injected mouse, the tumor surface temperature increased rapidly from 31.1 °C to 48.1 °C, and reached 51.8 °C after 300 s. The tumor surface temperature of  $Cu_{2-x}Se@mSiO_2-PEG/DOX$ injected mouse increased to 47.1 °C, a little lower than that of  $Cu_2$ .
- <sup>85</sup> <sub>x</sub>Se@mSiO<sub>2</sub>-PEG injected mouse, but it was still high enough to kill the cancer cells in vivo. More importantly, the anticancer drug DOX could rapidly release from nanoparticles for chemotherapy because of the thermal effect. These results reveal that both Cu<sub>2-x</sub>Se@mSiO<sub>2</sub>-PEG and Cu<sub>2-x</sub>Se@mSiO<sub>2</sub>-PEG/DOX
  <sup>90</sup> within the tumor can effectively adsorb and convert the NIR light to heat due to the deep penetration depth of 980 nm-wavelength laser light in biological tissues.<sup>20, 37,38</sup>

The mice were killed 8 h after photothermal therapy, and tumors were removed, embedded in paraffin, and cryo-sectioned <sup>95</sup> into 4 μ m slices. The slides were stained with hematoxylin/eosin (H&E). The histopathological images of the mouse treated by saline (Fig. 6b, S5a) show almost no cell necrosis after irradiation. Because saline solution merely converted very little light to heat and temperature of tumor surface only increased 3.5 °C,which is <sup>100</sup> not high enough to kill the cancer cells. The histopathological images of the Cu<sub>2-x</sub>Se@mSiO<sub>2</sub>-PEG treatment are shown in the Fig 6c and Fig S5b. Clearly, the common features of

thermonecrosis are presented on most areas of the examined tumor slide, such as cells shrinkage, loss of contact, coagulation, nuclear damage. Further, the histopathological images of the Cu<sub>2-x</sub>Se@mSiO<sub>2</sub>-PEG/DOX treatment showed that almost all of the <sup>5</sup> tumor tissue was necrotized, exhibiting degradation and corruption of the extracellular matrix of the tumor in the examined tumor slide (Fig 6d, Fig S5c). The enhanced cell necrosis proportion of the Cu<sub>2-x</sub>Se@mSiO<sub>2</sub>-PEG/DOX treatment could probably be attributed to synergistic interaction between

<sup>10</sup> chemotherapy and photothermal therapy due to enhanced toxicity of DOX and hyperthermia,<sup>47,48</sup> both of which were activated simultaneously by 980 nm laser.



**Fig.** 7 (a) The osteosarcoma tumor growth curves of different <sup>15</sup> groups after treatments. (b) Body weights of different groups mice after various treatments.

In order to further verify the enhanced anticancer effect of chemo-photothermal therapy by Cu<sub>2-x</sub>Se@mSiO<sub>2</sub>-PEG/DOX nanocomposites in vivo, we then compared the in vivo <sup>20</sup> therapeutic efficiency of saline, DOX, Cu<sub>2-x</sub>Se@mSiO<sub>2</sub>-PEG and Cu<sub>2-x</sub>Se@mSiO<sub>2</sub>-PEG/DOX by measuring tumor growth rates. The mice of osteosarcoma tumor model were randomly divided into four groups. The four groups were intratumorally injected into the tumor site, and then subjected to laser illumination (980 <sup>25</sup> nm, 0.72 W/cm<sup>2</sup>) for 10 min. The tumor sizes and body weights

of each group after treatments were then measured. The results demonstrated that the tumors treated with PBS grew obviously over time, suggesting that the osteosarcoma tumor growth was

not affected by laser irradiation (Fig.7a, S6). The growth of 30 tumors was inhibited in a certain degree by free DOX as compared with PBS. The mean tumor size in the Cu<sub>2-</sub> <sub>x</sub>Se@mSiO<sub>2</sub>-PEG group was much smaller than that of the PBS group, which demonstrates that the tumor growth could be obviously inhibited by just the photothermal effect of the Cu<sub>2-</sub> 35 xSe@mSiO<sub>2</sub>-PEG composites. The combination of the photothermal therapy and chemotherapy offered by Cu2-<sub>x</sub>Se@mSiO<sub>2</sub>-PEG/DOX nanocomposites under laser irradiation showed significantly an enhanced antitumor activity and even resulted in complete eradication of tumor(Fig. S6). These results 40 could probably be attributed to a synergistic effect between the chemotherapy and photothermal therapy due to enhanced cytotoxicity of DOX at elevated temperatures and higher heat sensitivity for the cells exposed to the DOX,<sup>47,48</sup> and continuous release of the DOX from the Cu2-xSe@mSiO2-PEG/DOX 45 nanocomposites, inhibiting tumor growth for a long time. During the treatments, we also measured the body weight of the mice for all groups, because a high toxicity usually leads to weight loss. For all groups, no obvious weight loss was found (Fig.7b), implying that the toxicity of treatments was low. Therefore, the 50 as-prepared Cu<sub>2-x</sub>Se@mSiO<sub>2</sub>-PEG nanoparticles driven by the NIR irradiation at the safe power density not only have good photothermal treatment ability, but also act as drug delivery carriers for cancer chemotherapy. Importantly, the combination of the photothermal therapy and chemotherapy significantly 55 improves the therapeutic efficacy, and demonstrates better therapeutic effects for cancer treatment than individual therapy in vivo. To the best of our knowledge, this is the first time to fabricate a combination of photothermal therapy and chemotherapy based on the Cu<sub>2-x</sub>Se nanomaterials. These results 60 revealed that the DOX loaded Cu<sub>2-x</sub>Se@mSiO<sub>2</sub>-PEG core-shell nanoparticles driven by NIR irradiation at the safe power density were a powerful agent for combining chemotherapy and photothermal therapy of cancer in vivo.

### 4. Conclusions

<sup>65</sup> In summary, the hydrophilic Cu<sub>2-x</sub>Se@mSiO<sub>2</sub>-PEG core-shell nanoparticles were successfully prepared, which possess high photothermal conversion effect and excellent biocompatibility in vitro. Moreover, the outer biocompatible mesoporous SiO<sub>2</sub> shell can protect the photothermal utilization of Cu<sub>2-x</sub>Se core in 70 complex biological environments and serve as a drug carrier for loading DOX for chemotherapy of cancer.

The release of DOX from the Cu<sub>2-x</sub>Se@mSiO<sub>2</sub>-PEG core-shell nanoparticles can be triggered by pH and NIR light, resulting in a synergistic effect for killing cancer cell. Importantly, we have <sup>75</sup> demonstrated that Cu<sub>2-x</sub>Se@mSiO<sub>2</sub>-PEG/DOX nanocomposites driven by the NIR radiation with safe power density showed significant enhancement of therapy effects on cancer cells than individual therapy approaches in vitro and in vivo. Therefore, Cu<sub>2-x</sub>Se@mSiO<sub>2</sub>-PEG/DOX core-shell nanocomposites integrate <sup>80</sup> the photohermal therapy and chemotherapy and have a great potential use for cancer therapy.

### Acknowledgements

95

105

115

120

130

This work was financially supported by the National Natural Scie nce Foundation of China (Grant Nos. 21171035 and 51302035), t he Key Grant Project of Chinese Ministry of Education (Grant No . 313015), the PhD Programs Foundation of the Ministry of Educ

- s ation of China (Grant Nos. 20110075110008 and 2013007512000
  1), the National 863 Program of China (Grant No. 2013AA03190
  3), the Science and Technology Commission of Shanghai Munici pality (Grant No. 13ZR1451200), the Fundamental Research Fun ds for the Central Universities, Program for Changjiang Scholars
- and Innovative Research Team in University (Grant No. IRT1221), the Shanghai Leading Academic Discipline Project (Grant No. B603), and the Program of Introducing Talents of Discipline to U niversities (No. 111-2-04).

## Notes and references

- <sup>15</sup> <sup>a</sup> State Key Laboratory for Modification of Chemical Fibers and Polymer Materials, College of Materials Science and Engineering, Donghua University, Shanghai, China. E-mail: hu.junqing@dhu.edu.cn <sup>b</sup> College of Chemistry and Chemical Engineering, Shanghai University of Engineering Science, Shanghai, China.
- <sup>20</sup> <sup>c</sup> Department of Orthopaedics, Shanghai First People's Hospital, Shanghai Jiaotong University, 100 Haining Road, Hongkou District, Shanghai, China.
- <sup>d</sup> Center of Super-Diamond and Advanced Films (COSDAF), Department of Physics and Materials Science, City University of Hong Kong, Hong 25 Kong
  - <sup>e</sup> College of Chemistry, Chemical Engineering and Biotechnology, Donghua University, Shanghai, China.
  - † Electronic Supplementary Information (ESI) available: See DOI: 10.1039/b000000x/
- 30 ‡These authors contributed equally.
- K. Yang, H. Xu, L. Cheng, C. Sun, J. Wang and Z. Liu, Adv. Mater., 2012, 24, 5586-5592.
- Z. Zha, X. Yue, Q. Ren and Z. Dai, Adv. Mater., 2013, 25, 777-782.
- 35 3. Y. Hu, L. Meng, L. Niu and Q. Lu, ACS Appl. Mater. Interfaces, 2013, 5, 4586-4591.
- P. Matteini, F. Tatini, L. Luconi, F. Ratto, F. Rossi, G. Giambastiani and R. Pini, *Angew. Chem. Int. Ed.*, 2013, **52**, 5956-5960.
- 40 5. J. L. Li, D. Day and M. Gu, Adv. Mater., 2008, 20, 3866-3871.
- C. Ungureanu, R. Kroes, W. Petersen, T. A. M. Groothuis, F. Ungureanu, H. Janssen, F. W. B. van Leeuwen, R. P. H. Kooyman, S. Manohar and T. G. van Leeuwen, *Nano Lett.*, 2011, **11**, 1887-1894.
- 45 7. W. Dong, Y. Li, D. Niu, Z. Ma, J. Gu, Y. Chen, W. Zhao, X. Liu, C. Liu and J. Shi, *Adv. Mater.*, 2011, 23, 5392-5397.
- J. Kim, S. Park, J. E. Lee, S. M. Jin, J. H. Lee, I. S. Lee, I. Yang, J.S. Kim, S. K. Kim, M.-H. Cho and T. Hyeon, *Angew. Chem. Int. Ed.*, 2006, 45, 7754-7758.
- <sup>50</sup> 9. L. Au, D. Zheng, F. Zhou, Z.-Y. Li, X. Li and Y. Xia, *Acs Nano*, 2008, **2**, 1645-1652.
- S. E. Skrabalak, J. Chen, L. Au, X. Lu, X. Li and Y. Xia, *Adv. Mater.*, 2007, **19**, 3177-3184.
- 11. M. S. Yavuz, Y. Cheng, J. Chen, C. M. Cobley, Q. Zhang, M.
- <sup>55</sup> Rycenga, J. Xie, C. Kim, K. H. Song, A. G. Schwartz, L. V. Wang and Y. Xia, *Nat. Mater.*, 2009, **8**, 935-939.
- J. Chen, C. Glaus, R. Laforest, Q. Zhang, M. Yang, M. Gidding, M. J. Welch and Y. Xia, *Small*, 2010, 6, 811-817.
- H. Xiaoqing, T. Shaoheng, M. Xiaoliang, D. Yan, C. Guangxu, Z.
   Zhiyou, R. Fangxiong, Y. Zhilin and Z. Nanfeng, Nat.
- Nanotechnol., 2011, 6, 28-32.
   S. Tang, X. Huang and N. Zheng, Chem. Commun., 2011, 47,
- S. Tang, X. Huang and N. Zheng, *Chem. Commun.*, 2011, 47, 3948-3950.
   K. Maan, S. H. Lee and H. C. Chei, An Nume 2000, 2 2707.
- 15. H. K. Moon, S. H. Lee and H. C. Choi, *Acs Nano*, 2009, **3**, 3707-3713.

- J. T. Robinson, K. Welsher, S. M. Tabakman, S. P. Sherlock, H. Wang, R. Luong and H. Dai, *Nano Res.*, 2010, **3**, 779-793.
- K. Yang, L. Hu, X. Ma, S. Ye, L. Cheng, X. Shi, C. Li, Y. Li and Z. Liu, *Adv. Mater.*, 2012, 24, 1868-1872.
- 70 18. K. Yang, S. Zhang, G. Zhang, X. Sun, S.-T. Lee and Z. Liu, Nano Letters, 2010, 10, 3318-3323.
  - Y. Ma, S. Tong, G. Bao, C. Gao and Z. Dai, *Biomaterials*, 2013, 34, 7706-7714.
- Z. Chen, Q. Wang, H. Wang, L. Zhang, G. Song, L. Song, J. Hu,
   H. Wang, J. Liu, M. Zhu and D. Zhao, *Adv. Mater.*, 2013, 25, 2095-2100.
- M. Zhou, R. Zhang, M. Huang, W. Lu, S. Song, M. P. Melancon, M. Tian, D. Liang and C. Li, *J. Am. Chem. Soc.*, 2010, **132**, 15351-15358.
- 80 22. Q. Tian, M. Tang, Y. Sun, R. Zou, Z. Chen, M. Zhu, S. Yang, J. Wang, J. Wang and J. Hu, *Adv. Mater.*, 2011, 23, 3542-3547.
  - Q. Tian, F. Jiang, R. Zou, Q. Liu, Z. Chen, M. Zhu, S. Yang, J. Wang, J. Wang and J. Hu, *Acs Nano*, 2011, 5, 9761-9771.
- 24. Q. Tian, J. Hu, Y. Zhu, R. Zou, Z. Chen, S. Yang, R. Li, Q. Su, Y. Han and X. Liu, *J. Am. Chem. Soc.*, 2013, 135, 8571-8577.
  - C. M. Hessel, V. P. Pattani, M. Rasch, M. G. Panthani, B. Koo, J. W. Tunnell and B. A. Korgel, *Nano Lett.*, 2011, 11, 2560-2566.
  - K. Yang, J. Wan, S. Zhang, B. Tian, Y. Zhang and Z. Liu, Biomaterials, 2012, 33, 2206-2214.
- 90 27. Z. Zhang, L. Wang, J. Wang, X. Jiang, X. Li, Z. Hu, Y. Ji, X. Wu and C. Chen, *Adv. Mater.*, 2012, **24**, 1418-1423.
  - S. Shen, H. Tang, X. Zhang, J. Ren, Z. Pang, D. Wang, H. Gao, Y. Qian, X. Jiang and W. Yang, *Biomaterials*, 2013, 34, 3150-3158.
  - G. Song, Q. Wang, Y. Wang, G. Lv, C. Li, R. Zou, Z. Chen, Z. Qin, K. Hou, R. Hu and J. Hu, *Adv. Funct. Mater.*,2013, 23, 4281-4292.
- W. Fang, S. Tang, P. Liu, X. Fang, J. Gong and N. Zheng, *Small*, 2012, 8, 3816-3822.
- W. Fang, J. Yang, J. Gong and N. Zheng, *Adv. Funct. Mater.*, 2012, 22, 842-848.
- 100 32. Y. Wang, K. Wang, J. Zhao, X. Liu, J. Bu, X. Yan and R. Huang, J. Am. Chem. Soc., 2013, **135**, 4799-4804.
  - M. Zheng, C. Yue, Y. Ma, P. Gong, P. Zhao, C. Zheng, Z. Sheng, P. Zhang, Z. Wang and L. Cai, *Acs Nano*, 2013, 7, 2056-2067.
  - C. Wang, H. Xu, C. Liang, Y. Liu, Z. Li, G. Yang, H. Cheng, Y. Li and Z. Liu, *Acs Nano*, 2013, 7, 6782-6795.
  - X. Liu, X. Wang, B. Zhou, W. C. Law, A. N. Cartwright and M. T. Swihart, *Adv. Funct. Mater.*, 2013, 23, 1256-1264.
  - Z. L. Jiang, B. Dong, B. T. Chen, J. Wang, L. Xu, S. Zhang and H. W. Song, *Small*, 2013, 9, 604-612.
- 110 37. Z. Chen, L. Zhang, Y. Sun, J. Hu and D. Wang, *Adv. Funct. Mater.*, 2009, **19**, 3815-3820.
  - L. Zhang, Q. Tian, W. Xu, X. Kuang, J. Hu, M. Zhu, J. Liu and Z. Chen, J. Mater. Chem., 2012, 22, 18156-18163.
  - Y.K. Peng, C.W. Lai, C.L. Liu, H.C. Chen, Y.H. Hsiao, W.L. Liu, K.C. Tang, Y. Chi, J.K. Hsiao, K.E. Lim, H.E. Liao, J.J. Shyue and P.T. Chou, *Acs Nano*, 2011, 5, 4177-4187.
  - Q. Chen, K. Li, S. Wen, H. Liu, C. Peng, H. Cai, M. Shen, G. Zhang and X. Shi, *Biomaterials*, 2013, 34, 5200-5209.
  - 41. J. Choi, N. Kang, H. Y. Yang, H. J. Kim and S. U. Son, *Chem. Mater.*, 2010, **22**, 3586-3588.
  - 42. J.J. Wang, D.J. Xue, Y.G. Guo, J.S. Hu and L.J. Wan, J. Am. Chem. Soc., 2011, **133**, 18558-18561.
  - H. Chen, L. Shao, T. Ming, Z. Sun, C. Zhao, B. Yang and J. Wang, Small, 2010, 6, 2272-2280.
- 125 44. A. S. Karakoti, S. Das, S. Thevuthasan and S. Seal, Angew. Chem. Int. Ed., 2011, 50, 1980-1994.
  - 45. V. Cauda, C. Argyo and T. Bein, *J. Mater. Chem.*, 2010, **20**, 8693-8699.
  - 46. X. C. Qin, Z. Y. Guo, Z. M. Liu, W. Zhang, M. M. Wan and B. W. Yang, *J. Photochem. Photobiol.*, *B*, 2013, **120**, 156-162.
  - 47. S. M. Lee, H. Park and K. H. Yoo, *Adv. Mater.*, 2010, 22, 4049-4053.
  - H. Park, J. Yang, J. Lee, S. Haam, I. H. Choi and K. H. Yoo, *Acs Nano*, 2009, 3, 2919-2926.

TOC



A difunctional nanoplatform based on the Cu<sub>2-x</sub>Se@mSiO<sub>2</sub>-<sup>5</sup> PEG core-shell nanoparticles demonstrates an excellent biocompatibility and can be used for combining photothermaland chemotherapies driven by the NIR light radiation with a safe power density.